Prostate Cancer Clinical Trial

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Summary

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

At least 18 years of age.
Signed informed consent.
Life expectancy ≥ 12 weeks as determined by the Investigator.
Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.

Suspected recurrence of prostate cancer (PC) based on rising Prostate-specific antigen (PSA) after definitive therapy on the basis of:

Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per American Urological Association recommendation) or
Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per American Society for Therapeutic Radiology and Oncology-Phoenix consensus definition).
Negative or equivocal findings for PC on conventional imaging performed as part of standard of care workup within 60 days prior to Day 0.
The Eastern Cooperative Oncology performance status 0-2.
Adequate recovery from acute toxic effects of any prior therapy.
Estimated Glomerular Filtration Rate of 30 mL/min or higher.
Adequate liver function.
For participants who have partners of childbearing potential: Partner and/or participant must use a method of birth control with adequate barrier protection.

Exclusion Criteria:

Participants who received other investigational agents within 28 days prior to Day 0.
Participants administered any high energy (>300 kiloelectronvolts (keV)) gamma-emitting radioisotope within 5 physical half-lives prior to Day 0.
Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for PC.
Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

51

Study ID:

NCT05249127

Recruitment Status:

Active, not recruiting

Sponsor:

Clarity Pharmaceuticals Ltd

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Tower Urology
Los Angeles California, 90048, United States
GU Research Network
Omaha Nebraska, 68130, United States
New Mexico Cancer Center
Albuquerque New Mexico, 87109, United States
Carolina Urologic Research Center
Myrtle Beach South Carolina, 29572, United States
Urology San Antonio
San Antonio Texas, 78258, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

51

Study ID:

NCT05249127

Recruitment Status:

Active, not recruiting

Sponsor:


Clarity Pharmaceuticals Ltd

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider